Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $125.3 million.

  • Intellia Therapeutics' Operating Expenses fell 1860.01% to $125.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.3 million, marking a year-over-year decrease of 766.86%. This contributed to the annual value of $592.1 million for FY2024, which is 735.61% up from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Operating Expenses is $125.3 million, which was down 1860.01% from $124.2 million recorded in Q2 2025.
  • Intellia Therapeutics' Operating Expenses' 5-year high stood at $155.5 million during Q1 2022, with a 5-year trough of $52.9 million in Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $125.3 million (2025), whereas its average is $123.3 million.
  • Per our database at Business Quant, Intellia Therapeutics' Operating Expenses skyrocketed by 19411.39% in 2022 and then plummeted by 1989.35% in 2023.
  • Intellia Therapeutics' Operating Expenses (Quarter) stood at $93.3 million in 2021, then skyrocketed by 32.58% to $123.7 million in 2022, then grew by 11.58% to $138.0 million in 2023, then increased by 8.22% to $149.3 million in 2024, then decreased by 16.11% to $125.3 million in 2025.
  • Its Operating Expenses stands at $125.3 million for Q3 2025, versus $124.2 million for Q2 2025 and $137.4 million for Q1 2025.